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Biomarkers are potentially powerful tools for use in research and regulation. Their derivation from biologic specimens collected from human subjects
does, however, present many ethical implications. Ethical issues are relevant in almost each facet of human biomarker research studies: design,
identification and recruitment of subjects, handling and use of the data, and interpretation and communication of results. Researchers also face a
number of dilemmas when considering the use of human biologic specimens and new biomarkers. The mere fact that such markers are the result
of measurements in human specimens gives the appearance of being more accurate than traditional sources of information such as questionnaires
or environmental monitoring; yet, this may not always be the case. The meaning of the results of biomarker studies may be unclear because the
purpose of the study is usually for research rather than clinical purposes. There generally are no established normal ranges for biomarkers and the
interpretation of findings are often difficult. Researchers may not communicate these results to subjects or consider followup action because the
task may be too difficult or undefined, or the reaction of the subject cannot be anticipated. A wide range of practices in this regard exists among
researchers. Many questions remain unanswered about the use of biologic specimens. These include questions of ownership and access to speci-
mens. Related to this is the question of whether specimens collected for one research purpose can be used for an entirely different research pur-
pose. This is still an open question. Researchers and regulators may not be aware of the potential for biomarker information to affect the lives of
subjects and their families without sufficient protection of personally identifiable data and regulation of its use. It is incumbent on researchers to con-
sider these human subject questions whenever they are using human specimens or biomarkers. - Environ Health Perspect 103(Suppl 3):69-74
(1995)
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Introduction
The use of human biologic specimens is
integral to current advances in molecular
epidemiologic research and biotechnologic
development. In the environmental health
field, biomarkers collected from human
specimens are now being used to indicate
exposure, disease, or susceptibility (1).
Studies involving biologic markers have the
potential to involve a broad range of ethi-
cal, legal, and social issues. These studies
are characterized by the actual collection of
biologic specimens from individual sub-
jects. Biomarker assays on human speci-
mens have the potential to be powerful
research tools that can enhance medicine
and public health. The "social" power of
biologic information should be considered,
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however, before any biomarker data are
collected or used (2).
Some concerns associated with human
biomarker research stem from misconcep-
tions ofinvestigators and the general pub-
lic about the nature ofbiomarker research.
An important misconception is that direct
access to biologic material gives the
impression, if not the reality, of being
closer to the "truth" than studies using
subject self-reports, environmental expo-
sure measurements, or record review as
key data sources. In some instances, bio-
marker data may be the most valid infor-
mation; however, it can be subject to
measurement, analytic, and interpretative
errors. Even when biomarker data are
valid, there is a range ofproblems in inter-
pretation and in the use of the informa-
tion that can significantly affect
participants in research. From this, many
observers have voiced concern that the
information derived from biomarker
research may be improperly used or have
disastrous and unanticipated effects on
study subjects, or segments of society, or
both (2,3). Such potential misuse, how-
ever, is no reason to abandon this research.
Rather, it should be seen as an alert to sci-
entists and others concerned about bio-
marker research to take an active role in
guarding against potential problems.
In this article, we will review the
process ofconducting research on human
biomarkers and address the ethical issues
that arise at each step in the process. Our
goal is to illustrate some potential problems
and stimulate dialogue among scientists on
approaches to prevent them.
Design of Studies
The temporal design structure of bio-
marker research is important for identify-
ing human subject issues. Therefore, as
preface to the discussion of ethical con-
cerns, it is useful to describe the three tem-
poral types ofstudy design: contemporary,
future, and retrospective studies.
Contemporary studies are those in
which the specimens are collected and
assayed and the results disseminated within
a relatively short period. These may be
transitional (i.e., studies that validate a
marker in the laboratory and in the field)
or etiologic studies (4,5) in scope, and
cross-sectional, case-control, or case-
cohort in design.
Future studies are those that are either
targeted or open-ended. In a targeted study
subjects will be recruited over a long period
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and specimens may be stored or banked for
years. The actual study purpose and, hence,
the assays to be conducted are, however,
known. In contrast, an open-ended study is
one wherein specimens are banked because
it is believed to be a good idea and a unique
resource. Individual research projects will,
however, be determined years after the
actual specimen collection.
Retrospective studies have characteristics
ofboth ofthese other types. They involve
finding a bank ofcollected specimens, possi-
bly collected for purposes other than the
research originally anticipated, and linking
specimen assay results with some health out-
comes. For example, the JANUS bank in
Norway has been collecting blood specimens
for cancer research since 1973 (6). Suppose
a series ofspecimens from 1973 to 1978
were assessed for a certain marker and then
all those subjects were traced today for their
health status with the use ofScandinavian
cancer registers. Although the specimen col-
lection was performed long in the past, the
assays and linkage ofassay results to cancer
would be conducted in the present.
Each of these three types of study
designs may raise certain ethical issues
peculiar to it. Where these occur, they will
be highlighted in the subsequent sections.
Subject Recruitment and
Informed Consent
Subjects will be attracted or recruited in
ways that can have ethical implications. This
is particularly true ifsubjects are deceived or
coerced into participating in a study or are
given false expectations (e.g., we can tell if
you are sick or well) with respect to the
value ofthe study to the participant. For
example, a researcher can coerce a potential
subject directly (e.g., you may lose your job
ifyou don't participate) or by implication.
Communicating false expectations or using
pressure are patently dishonest and unethi-
cal. It is unlikely that such deception or
coercion would be overt, rather it would be
more subtle and difficult to detect.
During the recruitment ofstudysubjects,
the investigator, as amatterofcourse, should
clearly inform the subjects ofthe intent and
activities required for participation and of
possible side effects. At least for federally
funded research (e.g., 45 CFR Part 46), and
as a matter ofcurrently accepted practice in
most other research, the collection ofbio-
logic specimens requires that subjects be
told, in lay language, ofthe purposes and
risks ofa study, and the uses to which the
specimens will be put, as well as other infor-
mation. More and more peer-reviewed jour-
nals require statements by authors attesting
that subjects were fully informed and partici-
patedvoluntarily in the research.
Ensuring that each subject understands
the implications ofparticipating in a study
is difficult and there is no simple formula
for developing consent forms. Informed
consent documents vary in length and
complexity. Some are short recitations of
general concepts. Others are detailed pack-
ages, indicating specific test risks, types of
results, and notification that will occur. At
present, there is not a standard practice for
the degree of specificity required in
informed consent documents. For contem-
porary studies, those in which the speci-
mens are collected and the results are
analyzed within a short time frame, prac-
tices may vary but the issue ofresults noti-
fication is more clear cut than for future or
retrospective studies. Usually in contempo-
rary studies, the subjects are known and
they can be easily notified ofresults. With
future or retrospective studies, this notifica-
tion is more difficult.
A number of questions have arisen
about the extent to which the investigator
must go to inform the subject ofunknown
or unplanned use ofspecimens for past or
future research. A question continually
posed by researchers asks whether or not
specimens collected for one purpose can be
used for related or for distinctly different
research. For example, may blood speci-
mens banked in a cardiovascular study be
used to look for cancer markers?
Additionally, in some cases, specimens were
collected and banked before the Belmont
Commission's report of 1978, which set the
stage for current human subjects practices
(7). What is the responsibility of
researchers using pre-1978 specimens to
inform subjects who participated in studies
prior to 1978? In general, what is the long-
term responsibility ofthe researcher, or the
research institute, or agency, or all three to
keep the subjects informed of the use of
their specimen(s)? The answers have not
been clearly delineated for retrospective
studies. Different agencies or institutions
havewidely different practices.
When subjects are recruited, the
researchers should inform them ofthe risks
and benefits of participation; detail the
study activities; and describe, in general
terms, any possible use of data in the
future. Nevertheless, questions will remain
about unspecified future uses of studies.
What are the limitations of conducting
additional analyses which are unrelated to
the original studypurpose?
Some researchers may feel hamstrung by
human subject constraints that prohibit per-
formance ofadditional assays on banked
specimens. Some agencies permit this prac-
tice, others do not. A logical followup ques-
tion is: Are the rights ofsubjects disregarded
when unspecified assays are conducted on
specimens collected for another purpose?
This is an arguable question. The cutting
edge ofthe ethical issue may be more along
the line of what should be done when
results of these additional assays are
obtained. This will be discussed in a subse-
quentsection.
The banking and use ofspecimens also
raise the question of ownership ofspeci-
mens. Who has legal ownership ofspeci-
mens or the products ofspecimens? The
case where a clinician used a patient's speci-
mens to develop, patent, and profit from a
cell line illustrates how these matters are still
unresolved (8,9). Other questions ofaccess
involve whether other scientists or even
nonscientific interests, such as insurance
companies or employers, can obtain access
to bankedspecimens.
Privacy and Confidentiality
Biomarker information about individuals has
been useful in individual and group quanti-
tative risk assessments (10,11). This use has
been described from the vantage ofthe clini-
cian and researcher, and the information is
gathered with the consent and concurrence
ofthe subject. The subject consents to pro-
vide the specimens and corollary demo-
graphic and risk factor information, and
hence, cooperates in the specified research.
The subject generally does not consent or
implyconsent to distribution ofthe data in a
way that identifies him or her individually to
any other parties, such as employers, unions,
insurers, credit agencies, lawyers, etc.
Dissemination or revelation of results
beyond the explicit purposes for which
specimens were collected intrudes on sub-
jects' privacy. Inadvertent labeling ofa sub-
ject as "abnormal" or as "in the extremes of
a distribution ofmarker assay results" could
have a potentially deleterious impact on the
person's ability to obtain insurance, a job,
or credit; it also could affect the person
socially. The psychological impact is virtu-
ally unknown. Thus, as Nelkin and
Tancredi (2) note, some union leaders are
concerned that workers will bear a "genetic
scarlet letter" that theywill become "lepers"
or "genetic untouchables."
Although the records ofgovernment-
sponsored or funded studies will be main-
tained according to the Privacy Act of 1974
(PL93-579), this does not ensure that
records will never bedisclosed. Title 5 in the
Code ofFederal Regulations describes the
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conditions under which records held by the
federal government can be disclosed (5CFR
297.401). These are shown in 12 situations
written into the Privacy Act that permit
releasing information in identifiable form:
* The records are necessary to protect the
health and safety ofother persons.
* A researcher uses them only for statisti-
cal research.
* Agency officials, or groups working with
an agency, need the records for uses
compatible with the purpose for which
the information was collected.
* The records are needed by agency per-
sonnel, who need the records in perfor-
mance oftheir duties.
* The release ofrecords is required by law.
* The Bureau ofCensus needs the records
for census or surveywork.
* The national archives needs them for
historical purposes.
* Either house of Congress requests an
individual's records.
* The comptroller-general needs the records
for the GeneralAccounting Office.
* A court orders the records.
* A consumer reporting agency needs the
records to assist the federal government in
collecting aclaim owed the government.
* The records are requested under the
terms and conditions ofthe Freedom of
Information Act, and their release would
not invade an individual's privacy.
These conditions apply to most federal
record systems. Confidentiality may be
more assertively protected in studies spon-
sored by agencies within the Public Health
Service ifthe investigator obtains a special
clearance, provided by Section 308(d) of
the Public Health Service Act [42 U.S.C.,
242m(d)], which bars disclosure to any
party other than the subject.
In studies conducted by academic,
business, or labor researchers, standard
practices to maintain privacy and confiden-
tiality are generally followed (12). In these
situations, however, there is more leeway to
interpret the degree ofconfidentiality than
with federally conducted research since the
practices are voluntary.
Interpretation and
Communication ofTest
and Study Results
Researchers have a responsibility to inter-
pret biomarker tests correctly-not to let
themselves be deceived by the extensive
variation in genetic and biochemic individ-
uality. The inherent variability among
individuals influences the interpretation
and communication of biomarker data.
Motulsky (13) has aptly described this
variability:
Human physiognomy is unique and no
two human beings except identical
twins are alike. The involved genes
remain unknown. Remarkable genetic
individuality also exists for red cell and
tissue cell (HLA) groups, in enzymes
and proteins. Enzyme variation usually
is associated with variable enzyme lev-
els in the normal range, so a person's
exact activity level for a given enzyme
(i.e., high normal, average, low nor-
mal) may be genetically determined.
Most enzyme variation will lead to dif-
ferences in the speed ofbreakdown of
various substances. Protein variation
may lead to differential binding offor-
eign substances.... Variability at the
DNA level is more striking. Frequent
differences occur at the individual
nucleotide level (every 500 nucleo-
tides), as do size variations oflonger
stretches ofDNA (minisatellites). Most
such DNA variants are phenotypically
silent but often can be used as markers
for closely linked gene loci that specify
proteins that have physiologic, bio-
chemical, or immunologic effects.
This natural variability makes it essen-
tial to know the range ofbiomarker values
in a normal population. Depending on the
biomarker, the range of normality can be
quite extensive. A healthy level for some
individuals may indicate a health risk for
others. For example, it is well known that
the cholinesterase level in subjects not
exposed to organophosphorus insecticides
covers a wide interindividual range (e.g.,
plasma; men, 0.44-1.63 pH/hr; women,
0.24-1.59 pH/hr) (14). Hence, a 25%
change in the group mean may mask a
50% decrease in a fewsubjects.
Although manystudies involve biomark-
ers for which a normal range has not been
established, the researcher should nonethe-
less provide some perspective on results for
each subject. This could be accomplished by
providing subjects with their results, indicat-
ing the group mean and range and those for
any comparison group, and explaining the
lackofaknown normal range.
Interpreting studies that involve biologic
markers and relaying the results to the study
group pose a number ofother dilemmas.
One such dilemma arises because interpreta-
tion of results is often influenced by the
tension between group effects and individ-
ual effects (15). Research data may yield
information on group risks but not indicate
individual risk. This dilemma is characteris-
tic ofepidemiologic research and predates
studies using biologic markers. One ofthe
major potential advances ofmolecular epi-
demiology is the ability to obtain specific
information that may be predictive ofrisks
to individuals (11,16). This ability is not
new to epidemiologic research (17), but the
exquisite sensitivity ofindividual risk deter-
minations based on gene assessments puts
researchers and society in difficult positions
with respect to interpretation ofresults when
markers are notyetvalidated. The traditional
paradigm that epidemiologic research per-
tains to a group leaves individual study sub-
jects at a loss regarding the meaning of
results for them. Subjects may be able to
learn about significant group risks but may
not be able to obtain any meaningful infor-
mation about individual risks unless investi-
gators have developed risk functions thatwill
calculate individual risk. Still, institutional
review boards often require that study sub-
jects receive their own test results alongwith
someexplanation or interpretation as soon as
the individual results are available.
Epidemiologists have not yet agreed about
the language forthesecommunications.
The discordance between the meaning of
group and individual effects may be tem-
pered if the limitations of the biomarker
research are clearly communicated to the
subjects prior to their participation and rein-
forced during the explanation ofthe results.
Individuals participating in a "research"
study may misinterpret the purpose ofthe
study and believe it is a health study and the
results will tell them whether or not they are
"all right." Clearly, this misconception may
frustrate the subjects and researchers in stud-
ies that assess only a marker's validity or that
provide information useful in an epidemio-
logic, rather than a clinical, sense (18).
Nevertheless, some biomarker studies may
identifypotentially relevant clinical findings.
In most biomarker studies, typicallyonly
one or a few markers are used because ofthe
wide variances in human biomarkers. A sin-
gle marker assay rarelyshould be interpreted
in isolation. On an individual basis, the
findings should be confirmed by a repeat
test given at some later date. Other confir-
matory studies should be sought for group
results. When possible, batteries ofmarkers
may provide a fuller picture than would be
seenwith one or a few markers (15).
In studies that compare putatively
exposed and nonexposed individuals, the
results may indicate that exposure is con-
tinuing and that there is an exposure-
response relationship. Such a finding may
trigger the need for the researcher to
address this fact so that subjects can take
preventive or remedial action.
Volume 103, Supplement 3, April 1995 71SCHULTEAND SWEENEY
Any positive study using markers that
are considered biologic changes capable of
being part of a disease process should trig-
ger consideration of the need for medical
surveillance. Although this is a prudent
policy that may involve surveillance of
some subjects with false-positive test
results, it will at least allow true-positive
subjects to be candidates for early interven-
tion or therapy. Short of that, researchers
still should make a strong effort to describe
the limitations of biologic markers, to
counsel subjects and, in some cases to pro-
vide the subjects' personal physicians with
information regarding the state ofknowl-
edge about the markers.
The complexity and uncertainty (regard-
ing disease risks) ofbiomarker data may be
why researchers and agencies have been
reluctant to communicate biomarker test
and study results. Minimal disclosure of
results is furthered by the fact that many
biomarker findings have no clinical interpre-
tation and because ofanxiety about misin-
terpreting issues conjured up by terms such
as "mutation, gene rearrangement,
"DNA adducts," or "at increased risk" (15).
Nonetheless, some agencies require com-
plete and full disdosure ofall test and study
results to subjects (e.g., 45 CFR Part 46).
This is intended to be done in clear lan-
guage, understandable to the lay person
(study subject), and with an interpretation
about what it means to them regarding risk
and the need for followup. Subjects gener-
ally want to know if "they are all right."
Often biomarker research is not designed to
answer that question. This caveat needs to
be made clear in the informed-consent pro-
cedure and then reiterated in the result dis-
semination. Some subjects will be in the
extreme ofdistributions ofresults, suggest-
ing higher exposure, increased risk, or the
existence ofsome inherited characteristics
that could put them at risk given a particu-
lar exposure. Drawing such conclusions,
however, is often distressing to scientists
who believe the data cannot be interpreted
or summarized to that extent. Key in these
deliberations is the need to think not just as
a scientist but also as a clinical or public
health specialist and as an advocate for the
subjects. Thus, it may be useful to reflect on
whether the findings could indicate a possi-
ble individual or group risk. Put another
way, researchers should ask themselves if
they were the subjects, what would they
want to know about the results. The reflec-
tions should however, also include consider-
ation of how the information can be
misinterpreted. Such thinking can be con-
sidered paternalistic decision-making, which
has come to have negative connotations
indicating disregard, be it well intentioned
or nefarious, ofa person's right to selfdeter-
mination. A possible solution is to just tell
subjects what is found together with all the
uncertainties. This generally will suffice for
noncontroversial research. For controversial
research, a panel of representatives ofthe
involved and affected parties may be needed
to come to a consensus on the interpretation
or at least on the range ofinterpretations
and on possible followup actions. For these
types ofsituations, the best approach may
be the involvement ofthese parties at the
conceptualization ofthe study and through-
out the process, rather than only at the dis-
semination phase.
Communication to
Control Subjects
Interpretation ofbiomarkers also needs to
be assessed in terms ofpossible background
of the biomarkers in the general popula-
tion. Since biomarkers may represent expo-
sures from various sources and by various
routes, a baseline in people not exposed by
the route or source ofinterest is important.
For example, in a study of dioxin, serum
levels were measured in the unexposed ref-
erent population. These data were invalu-
able in determining that, although the
referent population was not exposed to
occupational sources ofdioxin, they all had
low serum levels of dioxin, presumably
caused by low-level environmental contam-
ination (19). Although it is still unresolved
whether the low levels ofdioxin in adults
cause obvious adverse outcomes, control
subjects will require some interpretation of
what the data mean.
Similarly, in a study ofhospital workers
exposed to ethylene oxide, nonexposed
control workers were found to have
hydroxyethyl hemoglobin adducts (20).
This means that other exogenous and
endogenous sources ofhydroxyethyl moi-
eties needed to be considered, and subjects
were apprised ofthis fact.
Responsibilities for Action
Studies that indicate excess frequency of
exposure markers may obligate researchers
or authorities to address the source of
exposure. For researchers, this may involve,
at the least, speculation as to the nature
of the source. For authorities, it may
involve investigation and efforts to control
exposure.
For markers ofeffect, the actions to be
considered may be primary or secondary
preventive ones. For example, a cytogenetic
finding such as increased sister chromatid
exchanges in a group of individuals, may
trigger the kinds ofenvironmental controls
needed to address exposure even though
these are nonspecific-effect markers.
The markers may also trigger ongoing
medical screening or monitoring for dis-
ease. If the marker is intermediate in the
disease process and still reversible, inter-
ventions, such as chemoprevention, may be
considered (21).
Markers of susceptibility, such as a
P450 genotype, are the most problematic
with regard to what actions can be taken.
Markers of susceptibility can be used in
research as effect modifiers indicating there
is interaction of two or more variables.
Routine monitoring or testing for markers
ofsusceptibility are not intended to diag-
nose manifest symptoms of illness or dys-
function; rather they are intended to
discover the truth behind appearances, that
is, to detect conditions that are latent,
asymptomatic, or predictive of possible
future problems (2). The use ofthese tests
in job placement, for example, can be dis-
criminatory per se, as well as when they are
correlated with various demographic char-
acteristics. This can occurwhen a markers's
frequency is predominantly found in ethnic
or racial groups that historically have been
discriminated against. Using biomarkers for
genetic screening can create various ethical
problems, and the many cautions have been
discussed elsewhere (22-25).
Dilemmasfor Researchers
Scientists like to think of gathering and
interpreting data as being independent
from the social and political context; but
this is not always possible, especially for
data from biologic monitoring ofworkers
or community residents (for example, near
a hazardous chemical source). In these and
other instances where there are current con-
troversies over health risks, communicating
the results ofsuch data cannot be separated
from the use ofthe data (3). Dissemination
ofrisk information from biomarker studies
or routine biomonitoring can have implica-
tions for citizens' and employees' rights to
privacy; confidentiality; and nondiscrimina-
tion with respect to employment, insur-
ance, medical removal protection, and
acceptability for loans. Hence, researchers
must be aware of the social power ofbio-
logic information (2).
When test and study results are dissem-
inated, subjects not onlywant the results to
be interpreted, they may want recommen-
dations on what to do about them. These
recommendations may range from obtain-
ing medical screening or surveillance to
Environmental Health Perspectives 72ETHICAL ISSUESAND USES OFHUMANMONITORING DATA
seeking environmental or behavioral
changes to avoid further exposures.
Although researchers or their research insti-
tutions generally have limited responsibil-
ity in implementing or obtaining followup
activities, they may have a responsibility to
point out relevant issues.
New scientific developments will exac-
erbate many of the issues discussed here.
The obstacles to understanding associations
between genetic predisposition and disease
are slowly evolving as the use ofsynthetic
probes, the polymerase chain reaction, and
automated DNA-sequencing machines
increase the efficiency and lower the cost of
large-scale use ofassays in human popula-
tions (22). With these innovations, the
temptation to use tests or markers before
they are validated (26) may increase. For
population studies, validation means not
only laboratory validation to see ifthe test
works but also epidemiologic validation
(26). This involves determining the predic-
tive value and characterizing such features
as the range ofnormal, background preva-
lence, variation byage, race, sex, etc.
There is also the temptation to believe
that finding a genetic polymorphism may
explain human behavior and disease. This
reductionist attitude occurs among scien-
tists who find genetic explanations more
attractive than complex "unmeasurable"
social explanations (27). The debate
between nature and nurture is likely to
continue even though, as Keller (28) notes,
"Most responsible advocates are, ofcourse,
careful to acknowledge the role of both
nature and nurture, but rhetorically, as well
as in scientific practice, it is 'nature' that
emerges as the decisive victor." This shift
to a genetic versus environmental explana-
tion is evident in the debate over genetic
susceptibilities ofworkers. The Office of
Technology Assessment (22) has described
the trend and provides a balanced appraisal
of the roles ofgenetic and environmental
factors.
Molecular biology has enhanced the
traditional determination of "predis-
position to disease" (previously based
on physical examination, family his-
tory, and lifestyle habits) by seeking
out and finding genes or markers
associated with disease. Individuals
found to have the gene or the marker
can then be identified, sometimes
with near certainty, to be candidates
for disease. Often, predisposition only
manifests in disease when there is an
accompanying environmental insult,
e.g., toxic substances, viruses, or other
disease. The influence ofthe environ-
ment, however, remains the wild card
in most cases, because possession of
the genetic predisposition alone may
be insufficient to cause disease. It is
likely that for some time modern sci-
ence will be more successful in identi-
fying the genes and the markers than
in identifying the environmental
agent(s) necessary for activation of
the predisposing genes.
Shifts in this debate in one direction or
the other can have large influences on
political and social responses to divergent
problems such as disease, homelessness and
behavior (28).
The capability and widespread use of
the technology to assess biomarkers may
result in the identification of population
subgroups at increased susceptibility or
risk ofdisease. Hornig (29) has concluded
that the central policy question is: how
should the variation in the sensitivity of
groups and individuals be taken into
account in environmental laws and regula-
tions? This question assumes an ease of
determination and accuracy in determin-
ing the existence and nature of sensitive
subgroups. However, scientific uncertain-
ties limit the identification of sensitive
subgroups and individuals. Moreover, a
susceptibility marker is only a statistical
indicator whose predictive value depends
on the frequency with which those with
that marker develop the expected disorder.
Often, as in the case of ankylosing
spondylitis, the arthritic condition linked
to HLA B-27, many more persons positive
for the gene remain disease free than actu-
ally become ill.
Implications of Biotechnologic
Developments
The techniques used in the assay of bio-
logic specimens are being developed in var-
ious disciplines such as molecular biology
and genetics, clinical and analytical chem-
istry, and toxicology. Coincident with the
use ofhuman biologic materials for public
health research are efforts to use these
materials for profit. This raises important
ethical, legal, and economic issues. The use
of human specimens in biotechnology
raises questions that have not been
answered in previous public policy deliber-
ations. The Office of Technology
Assessment (9) identified the following
problematic questions:
* Who owns a cell line-the human
source oforiginal tissues and cells or the
scientist who developed the cell line?
* Should biologic materials be sold, and if
so, what are the implications for equity
ofdistribution?
* Should disclosure, informed consent,
and regulatory requirements be modified
to cope with the new questions raised by
the increased importance and value of
human biologic materials?
These are novel and complex questions
that have difficult answers. Currently,
biotechnology is not specifically regulated.
Moreover, new forms of collaboration
between academe and business are becom-
ing more common. The traditional open
exchange of information is giving way to
more secretive and proprietary behaviors.
There is a need for a broad-based ethical
review of the issues related to these
biotechnological endeavors.
Conclusion
In conclusion, awareness of the social
power of biologic information presents a
tension for the research scientist using
human specimens and biologic markers.
This tension has been described in the
publication, "On Being a Scientist" by the
National Academy ofSciences (30). Three
themes are addressed in the report: the
relationship between the "objective" and
the "subjective" in scientific research, the
social mechanisms within science that con-
tribute to its authenticity; and, the wider
social responsibility of the scientist.
Although these questions have character-
ized science for centuries, they have partic-
ular relevance to the human subjects issues
in specimen collection, analysis, and inter-
pretation. Such research requires that sci-
entists be both objective and subjective.
They must be objective in determining the
rationale for the research, in designing it,
and implementing it. This includes accu-
rate portrayal of risks and benefits to
potential subjects during the recruitment
and consent phase and in interpreting and
communicating results. Researchers also
need a certain amount ofsubjectivity in
this process to adequately address concerns
from the vantage of subjects and other
interested sectors ofsociety and to provide
recommendations for preventive, remedial,
or clinical action. The report "On Being a
Scientist" (30) rejects the notion that
objectivity is the result ofeliminating sub-
jectivity. Rather, it is the result ofauthen-
tic subjectivity that is the result of
researchers being attentive, intelligent, rea-
sonable, and responsible with regard to the
potential impact oftheirwork (30).
With this as a framework, many issues
still need to be resolved. These include the
use of specimens for purposes for which
they were not collected, the extent of
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reporting back results, ownership ofspeci-
mens, use and interpretation of results.
These cannot be left solely to ethicists and
institutional review boards; scientists need
to participate in the discussions and con-
tribute theirviews and concerns.
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